INTRODUCTION
ABT-737 is a small-molecule, Bcl-2 (B-cell lymphoma 2) homology domain 3 mimetic that belongs to a new interesting class of cancer therapeutics that block apoptosis inhibitors. Apoptosis inhibitors are commonly overexpressed in tumor cells and seem involved in drug resistance. 1 Cancer therapies depend on intact apoptosis pathways and frequently utilize the intrinsic (mitochondrial) route triggered by the release of cytochrome c from the mitochondria and the subsequent activation of executor caspases 3 and 7 via caspase 9.
2 It can be controlled by a number of molecules, for example, anti-apoptosis members of the Bcl-2 family. ABT-737 binds with high affinity to, and thereby blocks, Bcl-2, Bcl-xL (Bcl extra large) and Bcl-w, whereas it also has low affinity for Mcl-1 (myeloid cell leukemia sequence 1). 1 As the tumor cell often has an activated apoptosis system currently on hold by the upregulation of apoptosis inhibitors, molecules that block these inhibitors can release the apoptosis cascade in the absence of external apoptosis-inducing drugs. 3 ABT-737 has shown efficacy in experimental models of B-cell malignancy among others. It induces apoptosis in chronic lymphocytic leukemia cells, 3, 4 acute lymphoblastic leukemia (ALL) cells, 5 primary follicular lymphoma cells and small-cell lung carcinoma cell lines. 4 In animal models, treatment with ABT-737 induces regression of established tumors and improves survival with a high percentage of cures. 4 Furthermore, ABT-737 has shown synergistic effects with several, against ALL commonly used, chemotherapies. 5, 6 The oral analog to ABT-737 (ABT-263; Navitoclax, AbbVie, North Chicago, IL, USA) has entered clinical phase I/II trials. 7 T cells expressing chimeric antigen receptors (CARs) have in several phase I/II studies demonstrated safety and promising results in patients with B-cell malignancies. [8] [9] [10] [11] T cells induce apoptosis via the extrinsic pathway by expression of Fas ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), tumor necrosis factor, granzymes and so on. This pathway activates caspases 8 and/or 10 that subsequently activates executor caspases 3 and 7. Caspase 8 may also cleave Bid that, in its truncated form, interferes with Bak and Bax to induce apoptosis via caspase 9, and hence T cells may also utilize the intrinsic pathway. 1 Granzyme B activates caspases 3/7 directly or induces apoptosis via Bid, whereas granzymes A and C induce apoptosis in a caspase-independent manner, involving DNA degradation, inhibition of DNA repair, loss of mitochondrial transmembrane potential and induction of reactive oxygen species. 12 It is an appealing strategy to combine drugs that utilize more than one apoptosis pathway to increase tumor cell death and avoid drug resistance. Therefore, we here propose to combine T-cell therapy with small-molecule drugs that block apoptosis inhibitors. In the present study, the effect of CD19-targeting CAR T cells combined with ABT-737 was investigated in an in vitro model of B-cell malignancy.
MATERIALS AND METHODS

Patient material
CD19-CAR construction and vector production
The second-generation CAR construct contained an antibody single-chain fragment targeting CD19 fused to the intracellular portion of CD3z and CD28. 9 The construct was inserted into a lentiviral backbone (pRRL-CMV, kind gift from Dr R Hoeben, Leiden, The Netherlands) using SacII and XhoI restriction enzymes purchased from New England Biolabs (Ipswich, MA, USA). Lentiviruses were produced by transfecting 293T cells with the pRRL-CMV plasmid as well as helper plasmids; pLP1 coding for gag and pol, pLP2 coding for rev and pLP1/VSVG coding for env (Invitrogen). Vector-containing supernatant was harvested at days 3 and 4, and concentrated by ultracentrifugation. Lenti-Mock virus was produced using the empty pRRL-CMV, and Lenti-GFP had a green fluorescent protein (GFP) insert downstream the cytomegalovirus (CMV) promoter. All batches of CAR and control lentivectors were produced in parallel, and on T-cell transduction, Lenti-CAR was always combined with the control vector produced simultaneously.
Generation of CAR T cells
Peripheral blood mononuclear cells were stimulated by 1 mg ml
anti-CD3 antibodies (OKT-3; Biolegend, San Diego, CA, USA) for 3 days. Interleukin 2 at 100 IU ml À 1 (Proleukin, Novartis, Basel, Switzerland) was added to the cultures and the next day (day 4) T cells were transduced. Briefly, 1 Â 10 6 cells were pelleted by centrifugation followed by addition of 100 ml lentiviral vector concentrate (derived from 20 mg pRRL-CMV backbone plasmid; 4 pg/T cell) and 10 mg Polybrene (SIGMA-ALDRICH, Saint Louis, MO, USA). The cells were incubated at 37 1C for 4 h, after which fresh medium and interleukin 2 were added. Cells were cultured in six-well plates using a total of 3 ml medium per well. Interleukin 2 at 100 IU ml
was added every other day. T cells were used in assays 10 days after transduction.
ABT-737
ABT-737 was purchased from Selleck Chemicals (Selleck Chemicals LLC, Houston, TX, USA) and diluted in dimethyl sulfoxide to a concentration of 10 mM. From this stock solution, ABT-737 was diluted in RPMI to a concentration of 250-2000 nM and subsequently sterile filtered.
Caspase-Glo 3/7 assay
The Caspase-Glo 3/7 apoptosis assay (Promega, Madison, WI, USA) was performed according to the instructions from the manufacturer. Briefly, tumor cells were cultured at a cell density of 4 Â 10 5 cells per ml and T cells (CAR and Mock) at a density of 4 Â 10 6 (1:10 ratio) in 96-well plates. Of each cell suspension, 25 ml was added to the wells. Cells were cultured in triplicates alone and in different combinations for 3-24 h at 37 1C, 5% CO 2 in a total volume of 50 ml. An equal amount of Caspase-Glo 3/7 substrate was added to the culture and subsequently incubated for 30 min. Plates were analyzed in the luminometer, Wallac VICTOR, 2 1420 multilabel counter (PerkinElmer, Waltham, MA, USA).
Viability assays
Cell metabolism was measured using the Alamar blue assay (Biosource International, Camarillo, CA, USA), according to the manufacturer's protocol, and analyzed on Emax precision microplate reader (Molecular Devices, Sunnyvale, CA, USA). Viability was counted manually using a Bü rker chamber and staining with Trypan blue solution 0.4% (SIGMA-ALDRICH).
Flow cytometry
Cells were stained for flow cytometry. Briefly, cells were washed with phosphate-buffered saline, 1% bovine serum albumin, centrifuged and incubated for 15 min at room temperature with antibodies targeting CD19 (clone: HIB19), major histocompatibility complex I (MHC I; clone: G46-2.6), MHC II (clone: L243), intercellular adhesion molecule 1 (ICAM-1; clone: HA58; BD Pharmingen), CD3 (clone: UCHT1), CD8 (clone: RPA-T8), CD80 (clone: 2D10), CD86 (clone: IT2.2), Fas (clone: DX2) or negative isotype control antibodies (Biolegend). Cells were washed and diluted in 250 ml phosphate-buffered saline with 1% paraformaldehyde before analysis using FACSCanto II (BD Biosciences, San Jose, CA, USA). When staining with propidium iodide (BD Biosciences), the cells were resuspended without fixative agent and propidium iodide was added just before analysis.
PCR
RNA from the cell lines were purified using the Qiagen RNeasy minikit supplemented with Qiagen RNase-free DNase Set according to the manufacturer's protocol (Qiagen, Hilden, Germany). Complementary DNA was synthesized using iScript complementary DNA synthesis kit from Bio-Rad (Bio-Rad Laboratories, Hercules, CA, USA). Expression of BCL-2, BCL-xL and MCL-1 was detected by PCR using the following primers: BCL-2 forward (Fw):
0 , both purchased from Cybergene (Cybergene, Stockholm, Sweden). Taq DNA polymerase with accompanying buffers from Invitrogen was used. All PCR reactions were run on Bio-Rad CFX96 Real-Time system (Bio-Rad Laboratories).
Western blot
Cells were harvested and washed with cold phosphate-buffered saline and resuspended in lysis buffer containing 1% NP-40, 0.1 M Tris-HCl, 0.15 M NaCl, 5 mM EDTA with protease inhibitors, 1.0 mM ZnCl 2 , 50 mM Na 2 MoO 4 , 10 mM NaF, 0.1 mM NaVO 3 , 1.0 mM PMSF, 1.0 mM DTT and 1 Â complete EDTA-free protease inhibitor (Roche, Mannheim, Germany). The protein extracts were fractionated on NuPAGE Bis-Tris pre-cast gels (Invitrogen), run in MOPS SDS running buffer using the Novex electrophoresis system. Protein was transferred to nitrocellulose membranes using the iBlot Dry Blotting system (Invitrogen). The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline (10 mM Tris-HCl, pH 7.7, 150 mM NaCl) with 0.1% Tween-20 and then incubated with the indicated primary antibodies overnight at 4 1C. Primary antibodies used were: MCL-1 (S-19) 1:1000 dilution, BCL-xL (H-62) 1:500 dilution and BCL-2 (C 21) 1:800 dilution, all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). After washing, the membrane was incubated with secondary horseradish peroxidase-conjugated secondary antibodies: a-rabbit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and a-goat (Dako, Glostrup, Denmark) diluted 1:4000. The bands were visualized using the enhanced chemiluminescence (ECL) system (Amersham Bioscience, Buckinghamshire, UK). Internal positive controls were used to verify the protocols for all molecules analyzed.
Statistical analysis
Statistical evaluations were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Differences between group generating P-values o0.05 were considered significantly different. Analyses are specified in the figure legends. cytometry and the results showed that the CD8 þ T-cell phenotype dominated, ranging from 53 to 82% (Figure 2b ). The CAR T cells were used in killing assay against the CD19 þ cell line Daudi to determine their activity. Cell death was indicated after coculture by staining cells with aCD19 and propidium iodide and analyzed by flow cytometry. CAR T cells specifically killed CD19 þ cells (Figure 2c ) and to further elucidate the killing mechanism, Daudi cells were analyzed for activation of the executor caspases 3 and 7 using a bioluminescent caspase 3/7 detection kit. CAR T cells activated caspase 3/7 upon coculture with Daudi cells indicating apoptosis induction (Figure 2d ). Mock-treated T cells did not trigger specific caspase activation in Daudi cells.
RESULTS
ABT
ABT-737 enhances T cell-induced apoptosis CAR T cells were established from healthy donors and tested together with ABT-737. In a 3-h assay, both ABT-737 and CAR T-cell therapy induced caspase 3/7 activation, an effect that was significantly increased when combining ABT-737 and CAR T cells (Figure 3a) . At 24 h, the effect of CAR T-cell therapy persisted, whereas the effect of ABT-737 was considerably decreased. However, the combination of ABT-737 and CAR T-cell therapy was still more efficient than monotherapy (Figure 3b ). CAR T cells established from patients may have a different quality than those from healthy individuals. We therefore produced 13 T-cell batches from children with pre-B-ALL and tested their efficacy against Daudi with and without the addition of ABT-737. The viability of patient CAR T cells was somewhat lower than that of T cells derived from healthy donors and the growth rate was not as efficient in some of the batches (data not shown). However, the viable cells could induce apoptosis in Daudi cells. CAR T-cell therapy was better than ABT-737 monotherapy but the combination was always more efficient to induce apoptosis in Daudi than each agent alone as shown by a mean fold increase of 1.9 ranging from 1.2 to 3.1 (Figure 3c ).
Similar mRNA levels but variable protein concentrations of Bcl-2 family members in B-cell lines The level of Bcl-2 family members varies in patients and was therefore investigated in a panel of five B-cell lines. First, the mRNA expression profile of BCL-2, BCL-xL and MCL-1 was determined by PCR (Figure 4a ). The results demonstrate that at all these apoptosis inhibitors were present in our panel cell lines although BCL-2 expression was lower in both Daudi and U-698 compared with the other cell lines. Furthermore, DG-75 had a low expression of BCL-xL, whereas all the five cell lines investigated had a similar MCL-1 expression level. In normal cells the protein equivalents of Bcl-2 family members are present at low levels. 18 In western blot analyses the cell lines demonstrated a variable protein level of these inhibitors (Figure 4b ). Nall-1 had high levels of Bcl-2 but low levels of Mcl-1. The other cell lines showed high levels of Mcl-1 but no (Daudi, U-698) or barely detectable levels of Bcl-2 (Karpas 422 and DG-75). Bcl-xL protein could not be detected in any of the cell lines. Internal positive controls were run for all markers to ensure a functioning protocol (data not shown).
Combination therapy improves tumor cell death in a panel of CD19 þ cell lines Because of the variable protein levels of the Bcl-2 family members, the benefit of apoptosis inhibitor blockade was investigated in the B-cell line panel. Daudi, Karpas 422 and Nall-1 were sensitive for ABT-737 monotherapy, whereas U-698 and DG-75 were not sensitive at 2000 nM (Figure 5a ). However, all lines were sensitive to CAR T-cell therapy, although DG-75 consistently showed caspase 3/7 activation to a lesser extent than the others (Figure 5b) . Similar to the previous data on Daudi alone, CAR T-cell therapy was always improved by the addition of ABT-737 (Figure 5c ).
ABT-737 affects target cell phenotype
The increased efficacy of adding ABT-737 could be attributed to a change of tumor cell phenotype with increased expression of T-cell recognition molecules or due to increased levels of death receptors. The expression of antigen-presenting molecules (MHC I and II), death receptors (Fas) and adhesion and costimulatory molecules (ICAM-I, CD80, CD86) was therefore investigated on the five tumor cell lines before and after ABT-737 treatment. The expression of these molecules was stable in U-698, DG-75 and Daudi, except for an increased level of MHC II in Daudi after ABT-737 treatment that should not affect CD8 þ CAR T-cell interactions. Karpas 422 showed a somewhat increased level of Fas, MHC II and ICAM-I after ABT-737 treatment, and Nall-1 revealed an increase in both Fas and MHC II, whereas the 
DISCUSSION
Resistance to apoptosis is a major obstacle for most cancer therapeutics and can arise because of overexpression of apoptosis inhibitors of the Bcl-2 family. 7 Such proteins are rapidly degraded in normal cells and will not have a biological relevance until situations arise when the cell needs protection from apoptosis. For example, immune cells commonly upregulate antiapoptosis molecules during stages of activation to avoid succumbing too fast due to activation-induced cell death, autoregulation after inflammation and so on. 19 As B cells are of immune cell origin, it is not surprising that B-cell malignancies commonly show an enhanced level of apoptosis inhibitors. 2, 7, 18 In B-cell malignancy, high levels of Bcl-2 and Mcl-1 have been associated with poor prognosis. 18 These proteins are specialized to inhibit the intrinsic apoptosis pathway via blocking Bak and Bax that are needed for the release of cytochrome c from the mitochondria, and hence the formation of the apoptosome, activation of caspase 9 and finally activation of the executor caspases 3 and 7.
2 Combining different chemotherapeutics has been investigated to overcome the threshold of apoptosis inhibitors. However, an analysis of therapy-resistant patients demonstrates that the malignant cells may then even further increase their levels of apoptosis inhibitors, resulting in a vicious circle of increased resistance mechanisms and failed therapeutic efficacy. 20 In the process of transformation, tumor cells may acquire genetic aberrations that make them prone to undergo apoptosis. 21 The role of apoptosis inhibitors is, hence, to buffer the apoptosis signaling, thereby raising the apoptosis threshold. Blockade of apoptosis inhibitors with small-molecule therapeutics will then release the apoptosis signaling cascade that will kill the tumor cells without further apoptosis-inducing agents. In the five B-cell lines used in this study, the expression of different Bcl-2 family members varied. Three of the cell lines (Daudi, Karpas 422 and Nall-1) rapidly activated the executioner caspases 3 and 7 on ABT-737 treatment but two were unchanged (U-698 and DG-75). High et al. 5 demonstrated that the established therapies L-asparginase, topotecan, vincristine and etoposide had synergistic effect with ABT-737 in a xenograft model. 5 The difference in sensitivity may lie in the expression level of molecules targeted by ABT-737. At the mRNA level, BCL-2, BCLxL and MCL-1 were all detected, but as the protein equivalents can be rapidly degraded the protein levels were evaluated as well. Karpas 422, DG-75 and Nall-1 had detectable Bcl-2 protein, although high levels were only seen in Nall-1. All of them had varying levels of Mcl-1 and, in this case, Nall-1 had the lowest level of Mcl-1. None of the cell lines had detectable protein levels of Bcl-xL. There was no convincing correlation of expression levels of these molecules to ABT-737 sensitivity, likely due to the multiblocking character of ABT-737. 1 The presence of these molecules may not only confer a target for ABT-737 but of course also render the cell lines insensitive, if expressed at high levels. For example, it has been suggested that levels of MCL-1 (low) and BCL-2 (high) correlate with in vivo sensitivity for ABT-737 in cell lines, whereas high expression of MCL-1 confers resistance to ABT-737. [22] [23] [24] Correspondingly, Nall-1 was the cell line most sensitive for ABT-737 in our panel.
Both ABT-737 and ABT-263 (Navitoclax) have already entered clinical trials and have 1 and 18 registered studies (www. clinicaltrials.gov), respectively. Because of its oral availability, ABT-263 is the most clinically utilized and has been proven safe in a published dose-escalation study in 55 patients with relapsed or refractory lymphoid tumors. 7 Although the T-cell levels were somewhat decreased in treated patients, it was not connected to opportunistic infections and it was not determined if the decrease was a reflection of underlying disease or a direct effect of ABT-263 on the T cells.
Increasing the apoptosis stimuli by combining small-molecule inhibitors with conventional, novel cancer drugs can potentiate treatment efficacy. 5, 6 Recombinant TRAIL has been combined with ABT-737 in in vitro settings. TRAIL induces apoptosis via the extrinsic death receptor-mediated pathway and ABT-737 was shown to enhance the efficacy of TRAIL even in cell lines in which ABT-737 monotherapy had no efficacy. 25 Therefore, combining T-cell therapy that also utilizes the extrinsic pathway with ABT-737 is an interesting option to increase T-cell efficacy. Gene engineered T cells are currently used in multiple clinical trials for B-cell malignancy and some of these have already reported safety data. [8] [9] [10] [11] Even if promising indications were given in a few of these studies, only one pilot trial (n ¼ 3) has shown long-term complete remission in two patients. 11 In this trial, the CAR molecule was modified to contain a 4-1BB signaling motif instead of the common CD28 motif. If this was the reason for success or if it depended on the use of the lentiviral gene delivery vehicle needs to be clarified in follow-up studies. It is reasonable that optimization of the CAR construct may lead to enhanced capacity of T-cell therapy. Another approach may be to sensitize the tumor cells to T-cell killing mechanisms using blockers of apoptosis inhibitors such as ABT-737. In the present study, CD19-targeting CAR T cells were used in an in vitro model system of B-cell malignancy to investigate the possibility to enhance T-cell killing efficacy. All five cell lines tested were sensitive to CAR T-cell monotherapy and three of them were also sensitive to ABT-737 monotherapy. Independently of their sensitivity to ABT-737, combination therapy was always better than either therapy alone. As the effect was greater than merely additive, it is possible that they even synergize. However, a larger study to titrate the concentrations of both ABT-737 and the T-cell ratios is needed to fully establish formal statistically significant synergy. Another mechanism than a direct combinatorial effect on the caspase cascades to enhance T-cell efficacy is possible. For example, Song et al. 25 demonstrated that ABT-737 synergized with TRAIL via upregulation of TRAIL-R2 expression, thereby overcoming resistance to apoptosis in otherwise TRAIL-resistant cell lines. Therefore, the expression of proteins on the tumor cell surface with and without ABT-737 treatment was investigated. We focused on receptors that could likely affect T-cell recognition, adherence, costimulation and killing. Most cell lines remained stable and even if Karpas 422 and Nall-1 had increased expression of Fas, and Karpas 422 also displayed a higher level of ICAM-1, they were not more sensitive than the other cell lines in killing assays.
As activated immune cells upregulate apoptosis inhibitors to avoid activation-induced cell death, the CAR T cells may also apoptose when exposed to ABT-737. In our study we show that different T-cell batches derived from separate donors may be divided into sensitive and less sensitive batches. As the T cells outnumber the tumor cells in killing assays, it may be an obstacle to the assay. Furthermore, T cells cultured alone for 24 h show decreased viability compared with those cultured with their CD19 þ target that receives activation signaling via the CAR. This also makes the Mock T cells more sensitive than the CAR T cells in these assays. It is, hence, important to include appropriate controls to withdraw background of the T cells alone, and also to not exceed too high T cell/tumor cell ratios. Whether T-cell death due to ABT-737 would be a clinical problem or benefit is difficult to dissect. If ABT-737 also selectively kills the therapeutic CAR T cells, it is a problem for efficacy. In an attempt to address this issue, a presensitization experiment was utilized in which the tumor cells were pretreated with ABT-737 and washed before coculture with CAR T cells. This experiment indicates that it may be possible to presensitize the tumor to CAR T-cell killing. A positive outcome of sensitivity of activated immune cells to ABT-737 may be a repression of activated T regulatory cells or even myeloid-derived suppressor cells. The effect of ABT-737 on these cell populations as well as T cells should be addressed in both in vitro and in vivo models to fully understand the biology and to find optimal treatment schedules. In a study by Begley et al., 26 it was shown that daily dosing of ABT-737 could be used in vivo in a murine colon carcinoma model (CT26) to potentiate dendritic cell immunotherapy by sensitizing the tumor cells to apoptosis, demonstrating the in vivo possibilities of combination therapies. However, this did not hold true for the B16 melanoma model in which both dendritic cell vaccination and pmel T cells were used in the same report. Neither did TRAIL, nor other inducers of the extrinsic apoptosis pathway, potentiate ABT-737 killing of B16 tumor cells in vitro, demonstrating possible differences between models or even between mice and humans.
Taken together, our data show that ABT-737 is an interesting small-molecule drug that has potential to increase the efficacy of CAR T cells even if the tumor cell is not sensitive for ABT-737 monotherapy. Furthermore, ABT-737 can possibly be used to presensitize the cells to T-cell therapy. This study warrants further elucidation of both the in vitro and in vivo effects of ABT-737/CAR T-cell combinatory therapy.
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